Is Thyrocare Technologies a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Thyrocare Technologies Ltd is a good quality company .

Is Thyrocare Technologies undervalued or overvalued?

The key valuation ratios of Thyrocare Technologies Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Thyrocare Technologies share price return in the past 10 years?

Data is not available for this company

Is Thyrocare Technologies a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Thyrocare Technologies Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Thyrocare Technologies?

The latest standalone P/E ratio of Thyrocare Technologies as of 20-Dec-2024 is 56.58.

What is the P/B ratio of Thyrocare Technologies?

The latest standalone P/B ratio of Thyrocare Technologies as of 20-Dec-2024 is 10.49.

What is the 52-week high and low of Thyrocare Technologies?

The 52-week high of Thyrocare Technologies is Rs. 1050.65 and the 52-week low is Rs. 555.85.

Thyrocare Technologies Ltd - Stock Valuation and Financial Performance

Name: Thyrocare Technologies
Brand: Thyrocare Technologies

BSE: 539871 | NSE: THYROCARE | Hospital & Healthcare Services | Small Cap

Place order

Thyrocare Tech. Share Price

₹948.75 -24.80 -2.55%
as on 20-Dec'24 16:59

10 Year X-Ray of Thyrocare Tech.:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	24.6%	25.7%	21%	33.9%	31.5%	35.3%	38.5%	48.4%	17.6%	18.8%	-
Value Creation Index ⓘ	0.8	0.8	0.5	1.4	1.3	1.5	1.8	2.5	0.3	0.3	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	183	241	304	356	403	434	495	589	527	572	623
Sales YoY Gr.	-	31.7%	26.3%	17.1%	13.1%	7.8%	13.9%	19.1%	-10.6%	8.6%	-
Adj EPS ⓘ	8.9	9.5	11.5	16.9	15.5	17	20.1	29.7	12.4	13.5	15.9
YoY Gr.	-	6.9%	21.1%	46.8%	-8.6%	9.9%	18.4%	47.9%	-58.2%	9%	-
BVPS (₹) ⓘ	54.5	67.6	75	82	81.7	68.7	80.3	98.9	100.1	98.7	92.1
Adj Net Profit ⓘ	45	51.1	62	90.9	81.6	89.8	106	157	65.7	71.7	84
Cash Flow from Ops. ⓘ	34.5	67.8	89.6	107	100	168	115	113	129	168	-
Debt/CF from Ops. ⓘ	0	0	0.1	0	0	0	0	0	0	0.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	13.5%	7.3%	5%	8.6%
Adj EPS ⓘ	4.8%	-2.6%	-12.4%	9%
BVPSⓘ	6.8%	3.9%	7.1%	-1.4%
Share Price	-	11.9%	-0.2%	44%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	16.3	15.9	16	21.4	18.6	22.4	26.8	33	12.4	13.5	16.6
Op. Profit Mgn % ⓘ	39.9	39.1	38.3	40.9	38.3	40	34.7	40	23.4	24.4	25.1
Net Profit Mgn % ⓘ	24	21.2	20.4	25.5	20.2	20.6	21.8	26.7	12.2	12.3	13.5
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	0	0
Working Cap Days ⓘ	0	60	51	44	42	47	59	154	240	131	72
Cash Conv. Cycle ⓘ	0	19	19	15	13	3	7	31	58	33	46

Recent Performance Summary

Sales growth is good in last 4 quarters at 13.73%

Return on Equity has declined versus last 3 years average to 16.60%

Sales growth has been subdued in last 3 years 4.96%

Net Profit has been subdued in last 3 years -12.35%

Latest Financials - Thyrocare Technologies Ltd.

	Standalone	Consolidated
TTM EPS (₹)	16.8	15.9
TTM Sales (₹ Cr.)	571	623
BVPS (₹.) ⓘ	90.4	92.1
Reserves (₹ Cr.) ⓘ	511	435
P/BV ⓘ	10.49	10.30
PE ⓘ	56.58	59.87

From the Market
52 Week Low / High (₹)	555.85 / 1050.65
All Time Low / High (₹)	406.65 / 1465.90
Market Cap (₹ Cr.)	5,028
Equity (₹ Cr.)	53
Face Value (₹)	10
Industry PE ⓘ	43.2

Management X-Ray of Thyrocare Tech.:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

100.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Thyrocare Tech.

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Thyrocare Tech.

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	183	241	304	356	403	434	495	589	527	572
Operating Expenses ⓘ	110	147	189	212	249	261	323	353	404	433
Manufacturing Costs	8	11	13	12	16	19	17	23	30	38
Material Costs	56	70	81	95	111	117	164	170	163	167
Employee Cost	17	26	32	35	43	49	58	61	106	108
Other Costs ⓘ	29	40	62	69	79	76	84	99	105	120
Operating Profit ⓘ	73	94	115	145	154	174	171	236	123	139
Operating Profit Margin (%)	39.7%	39.0%	37.9%	40.6%	38.3%	40.0%	34.6%	40.0%	23.3%	24.3%
Other Income ⓘ	8	7	12	23	10	7	12	29	8	9
Interest ⓘ	0	1	0	0	1	2	1	3	5	6
Depreciation ⓘ	13	18	18	20	26	32	30	34	39	47
Exceptional Items ⓘ	0	0	-27	-2	0	-7	0	0	0	0
Profit Before Tax ⓘ	68	82	82	145	138	140	152	228	89	96
Tax ⓘ	24	30	39	52	53	52	39	52	24	26
Profit After Tax	44	52	43	93	85	88	113	176	64	69
PAT Margin (%)	24.1%	21.5%	14.1%	26.2%	21.1%	20.4%	22.9%	29.9%	12.2%	12.2%
Adjusted EPS (₹)	9.0	9.6	8.0	17.4	16.2	16.8	21.1	33.3	12.5	13.4
Dividend Payout Ratio (%)	42%	104%	125%	57%	124%	30%	118%	45%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	276	363	403	440	431	363	424	523	530	522
Share Capital ⓘ	51	54	54	54	53	53	53	53	53	53
Reserves ⓘ	225	309	349	387	378	310	371	470	477	469
Minority Interest	36	0	0	0	0	0	0	0	1	1
Debt	0	0	7	0	3	3	0	0	0	13
Long Term Debt	0	0	7	0	3	3	0	0	0	11
Short Term Debt	0	0	0	0	0	0	0	0	0	2
Trade Payables	1	2	1	7	8	22	25	17	24	40
Others Liabilities ⓘ	16	42	23	27	28	82	91	308	206	53
Total Liabilities ⓘ	328	407	434	474	470	469	540	848	761	629
Fixed Assets
Gross Block	237	318	277	336	355	359	366	423	461	501
Accumulated Depreciation	41	59	18	37	61	90	113	138	167	195
Net Fixed Assetsⓘ	196	259	259	299	294	269	253	285	294	306
CWIP ⓘ	6	1	17	0	1	5	8	3	2	3
Investmentsⓘ	86	93	104	120	95	90	126	146	144	162
Inventories	7	11	14	17	18	21	23	25	28	48
Trade Receivables	5	8	6	10	12	16	45	93	85	43
Cash Equivalents	5	10	12	12	10	11	16	14	28	40
Others Assetsⓘ	24	25	21	16	39	57	69	282	180	27
Total Assets ⓘ	328	407	434	474	470	469	540	848	761	629

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	34	68	90	107	100	168	115	113	129	168
PBT ⓘ	68	82	82	145	137	146	153	228	87	96
Adjustment ⓘ	6	17	43	9	24	32	23	21	65	71
Changes in Working Capital ⓘ	-17	1	6	2	-1	34	-18	-79	6	30
Tax Paid ⓘ	-23	-32	-40	-49	-61	-45	-43	-57	-28	-29
Cash Flow From Investing Activity ⓘ	-18	-18	-42	-43	-12	1	-49	-24	-39	-91
Capex	-10	-14	-36	-44	-39	-10	-21	-15	-42	-61
Net Investments	46	-7	-10	-4	26	10	-32	-9	1	-31
Others ⓘ	-54	3	5	4	2	1	5	1	1	1
Cash Flow From Financing Activityⓘ	-23	-45	-49	-64	-94	-165	-62	-89	-86	-85
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	3	0	0	0	0	22
Interest Paid ⓘ	0	0	0	0	0	0	0	-2	-2	-7
Dividend Paid ⓘ	-19	-38	-40	-54	-27	-132	-53	-79	-79	-95
Others ⓘ	-4	-7	-8	-10	-69	-33	-9	-8	-5	-5
Net Cash Flow ⓘ	-6	5	0	0	-5	4	4	0	4	-8

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	15.98	16.22	11.19	22.12	19.53	22.26	28.75	37.18	12.23	13.21
ROCE (%)	24.57	25.66	21.04	33.89	31.48	35.27	38.51	48.42	17.61	18.75
Asset Turnover Ratio	0.56	0.66	0.72	0.79	0.85	0.93	0.98	0.85	0.65	0.82
PAT to CFO Conversion(x)	0.77	1.31	2.09	1.15	1.18	1.91	1.02	0.64	2.02	2.43
Working Capital Days
Receivable Days	10	9	8	8	10	12	23	43	62	41
Inventory Days	15	14	15	16	16	16	16	15	18	24
Payable Days	5	7	7	15	23	46	52	45	45	70

Thyrocare Technologies Ltd Stock News

Thyrocare Technologies Ltd FAQs

What is the share price of Thyrocare Tech.?

Company share prices are keep on changing according to the market conditions. The closing price of Thyrocare Tech. on 20-Dec-2024 16:59 is ₹948.8.

What is the market cap of Thyrocare Tech.?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Thyrocare Tech. stood at ₹5,027.6.

What is the P/E ratio of Thyrocare Tech.?

The latest P/E ratio of Thyrocare Tech. as of 20-Dec-2024 16:59 is 56.58.

What is the P/B ratio of Thyrocare Tech.?

The latest P/B ratio of Thyrocare Tech. as of 20-Dec-2024 16:59 is 10.49.

What is the 52-week high and low of Thyrocare Tech.?

The 52-week high of Thyrocare Tech. is ₹1,050.7 and the 52-week low is ₹555.9.

What is the TTM revenue of Thyrocare Tech.?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Thyrocare Tech. is ₹570.8 ( Cr.) .

About Thyrocare Technologies Ltd

Thyrocare Technologies Ltd. is India's first and most advanced Totally Automated Laboratory having its strong presence in several cities / towns in India and internationally. Thyrocare is India's first fully automated diagnostic laboratory with a focus on providing quality at affordable costs to laboratories and hospitals in India and other countries. Thyrocare operates with a Centralized Processing Laboratory (CPL) in Mumbai - India for esoteric tests; and Regional Processing Laboratory in major metro cities of India and other parts of Asia. It has focus on strong technologies, strong brands and strong systems that enable all laboratories to give their clients the best of science and technology at an affordable cost. Thyrocare became one of the first Indian diagnostic laboratories to obtain internationally renowned quality accreditations like ISO 9001-2000 rating as early as 2001, which is now escalated to ISO 9001:2008 and CAP (College of American Pathologists) certification in 2007.

Business area of the company

Thyrocare Technologies is an India-based healthcare service provider. The Company operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The Company offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The Company offers cancer diagnosis and water testing through its brands Nueclear and Whaters, respectively.

Major events and milestones

2000: The company was incorporated in the name and style of ‘Thyrocare Technologies Limited’ and received a certificate for commencement of operations.
2001: The company received ISO 9001 certification.
2001: The company commenced commercial operations under the brand name ‘Thyrocare’ pursuant to the acquisition of business of TDPL and TBPL (which were incorporated in 1996).
2005: The company received NABL accreditation.
2006: The company issued certain fully convertible debentures aggregating to Rs 250 million to BCCL.
2007: The company receives accreditation from the College of American Pathologists (CAP).
2010: The company issued certain compulsorily convertible debentures aggregating to Rs 250 million to Agalia. Agalia also acquired certain Equity Shares aggregating to Rs 1,250 million from its Promoters and certain other persons.
2010: The company launched wellness packages under the brand name ‘Aarogyam’.
2011: The company migrated to ‘total laboratory automation system’ installed by Siemens for efficient handling of increasing volumes.
2012: NVP acquired certain Equity Shares aggregating to Rs 1,200 million from certain entities.
2013: EIF acquired certain Equity Shares from Agalia.
2013: The company’s subsidiary commenced operations at the PET-CT centres at Navi Mumbai and conducted over 1,000 scans in the first year of operation.
2014: The company had installed, India’s first and the world’s longest track automation system for seamless sample movements from Siemens Limited.
2014: The company commissioned the operations in medical cyclotron facility in Navi Mumbai.
2014: The company’s subsidiary commenced operations at the PET-CT centres in New Delhi and Hyderabad and the PET-CT centres at New Delhi conducted over 1,000 scans in the first year of operations.
2015: The company opened RPLs in Delhi, Coimbatore, Hyderabad and Kolkata to expand its coverage and volume of tests and samples processed daily.
2015: The company acquired the equipment for testing of water samples and commenced operating the equipment under the brand name ‘WHATERS’. These tests, at present, include physical and chemical testing, elements testing, microbiology testing, pesticide testing and volatile organic compounds testing.
2015: The company’s subsidiary has completed over 10,000 scans at the PET-CT centres in New Delhi, over 10,000 scans at the PET-CT centres in Navi Mumbai from the date of inception and over 1,000 scans at the PET-CT centres in Hyderabad since inception.
2015: The Company opened RPLs in Delhi, Coimbatore, Hyderabad and Kolkata to expand its coverage and volume of tests and samples processed daily.
2015: The Company acquired the equipment for testing of water samples and commenced operating the equipment under the brand name ''WHATERS''. These tests, at present include physical and chemical testing, elements testing, microbiology testing, pesticide testing and volatile organic compounds testing.
2015: The Subsidiary has completed over 10,000 scans at the PET-CT centres in New Delhi, over 10,000 scans at the PET-CT centres in Navi Mumbai from the date of inception and over 1,000 scans at the PET-CT centres in Hyderabad since inception.
2016: Thyrocare Technologies are listed and admitted to dealings on the Exchange in the list of 'B' Group Securities.
2016: Entered the Public listed sphere of healthcare – IPO.
2016: Launched 2 new RPLs and NGSP Certification:- Certified with National Glycohemoglobin Standardization Program Certification (NGSP) for HbA1c Testing, and Launched 2 Regional Processing Laboratories- Bhopal and Bangalore, with state-of-the-art automations efficient as CPL, controlled via a centralized server.
2016: Aarogyam Today: Launched a second monthly publication addressing daily health concerns - Aarogyam Today.
2016: Launched IFA (Immunofluorescence) for Autoimmunity testing.
2017: Launched Molecular Biology Division (PCR).
2018: Patna Regional Processing Laboratory (RRL) was launched.
2018: Last Mile Executive (LMEs) pickup service started in 15 plus cities.
2018: Thyrocare and Thyroshop Mobile App were launched.
2020: Thyrocare Technologies launching Blood-based Cancer Screening Profile.